Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 990.40
Bid: 990.60
Ask: 991.00
Change: 10.20 (1.04%)
Spread: 0.40 (0.04%)
Open: 979.00
High: 991.00
Low: 977.80
Prev. Close: 980.20
SN. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition

5 Jan 2016 07:00

RNS Number : 7712K
Smith & Nephew Plc
05 January 2016
 

 

 

 

Smith & Nephew completes acquisition of surgical robotics business Blue Belt Technologies

 

5 January 2016

 

 

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces it has completed the acquisition of Blue Belt Holdings, Inc. ("Blue Belt Technologies"), securing a leading position in the fast-growing area of orthopaedic robotics-assisted surgery.

 

Blue Belt Technologies' Navio surgical system currently provides robotics-assistance in unicondylar or partial knee replacement surgery through CT-free navigation software and a unique hand-held, robotic bone-shaping device. Navio and Smith & Nephew's partial knee implant portfolio form a strong combined business from which to accelerate growth in this attractive area of surgery. Additionally, the Group intends to expand the Navio platform into total knee, bi-cruciate retaining knee and revision knee implants, delivering significant further upside.

 

Enquiries

 

InvestorsIngeborg ØieSmith & Nephew

 +44 (0) 20 7960 2285

 

Financial MediaCharles ReynoldsSmith & Nephew

+44 (0) 20 7401 7646

 

Ben Atwell / Matthew ColeFTI Strategic Consulting

 

+44 (0) 20 3727 1000

 

Trade Media

Joe Metzger

Smith & Nephew

 

 

+1 (978) 749-1330

 

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 14,000 employees and a presence in more than 100 countries. Annual sales in 2014 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

 

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

 

◊Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQEAKFLEEDKEFF
Date   Source Headline
3rd Aug 20237:00 amRNSHalf-year Report
1st Aug 202312:37 pmRNSTotal Voting Rights
21st Jul 20231:45 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSNotice of Results
3rd Jul 20234:07 pmRNSTotal Voting Rights
30th Jun 202310:21 amRNSDirector Declaration
1st Jun 202312:30 pmRNSTotal Voting Rights
24th May 20234:45 pmRNSDirector/PDMR Shareholding
19th May 20234:15 pmRNSDirector/PDMR Shareholding
5th May 20237:08 amRNSDividend Declaration
5th May 20237:00 amRNSDirector Declaration
3rd May 20239:30 amRNSDirector/PDMR Shareholding
2nd May 20231:53 pmRNSTotal Voting Rights
27th Apr 20233:25 pmRNSDirector/PDMR Shareholding
26th Apr 20233:36 pmRNSResult of AGM
26th Apr 20237:00 amRNSQ1 2023 Trading Update
6th Apr 20237:00 amRNSNotice of First Quarter 2023 Trading Report
3rd Apr 20232:07 pmRNSTotal Voting Rights
13th Mar 20231:45 pmRNSDirector/PDMR Shareholding
6th Mar 20236:00 pmRNSAnnual Financial Report
1st Mar 20232:44 pmRNSTotal Voting Rights
22nd Feb 20231:07 pmRNSDirector/PDMR Shareholding
21st Feb 20231:41 pmRNSDirector/PDMR Shareholding
21st Feb 20237:00 amRNSFinal Results
17th Feb 20237:00 amRNSDirectorate Change
1st Feb 20234:15 pmRNSBlock listing Interim Review
1st Feb 202311:20 amRNSTotal Voting Rights
26th Jan 202312:22 pmRNSNotice of Results
19th Jan 20233:19 pmRNSDirector/PDMR Shareholding
3rd Jan 20231:47 pmRNSTotal Voting Rights
12th Dec 20224:37 pmRNSDirector/PDMR Shareholding
9th Dec 202211:30 amRNSDirector/PDMR Shareholding
1st Dec 20222:00 pmRNSTotal Voting Rights
16th Nov 202211:30 amRNSDirector/PDMR Shareholding
10th Nov 20227:00 amRNSDirector/PDMR Shareholding
3rd Nov 20227:00 amRNS3rd Quarter 2022 Trading Report
1st Nov 202210:38 amRNSTotal Voting Rights
28th Oct 202211:45 amRNSDirector/PDMR Shareholding
14th Oct 20227:01 amRNSDividend Declaration
14th Oct 20227:00 amRNSTiming of Smith & Nephew Q3 2022 Trading Update
5th Oct 20227:00 amRNSEuro Bond Issue
3rd Oct 202212:53 pmRNSTotal Voting Rights
14th Sep 20223:00 pmRNSDirector/PDMR Shareholding
1st Sep 20221:33 pmRNSTotal Voting Rights
1st Sep 20227:00 amRNSBoard Committee Membership
23rd Aug 20225:05 pmRNSDirector/PDMR Shareholding
23rd Aug 20224:25 pmRNSDirector/PDMR Shareholding
16th Aug 20224:57 pmRNSDirector/PDMR Shareholding
12th Aug 20225:40 pmRNSTransaction in Own Shares
12th Aug 20224:45 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.